Get the Stockscreener App
138.23
3.02%
-4.30
Pre-market:
139.01
0.78
+0.56%
Celcuity Inc stock is traded at $138.23, with a volume of 661.18K.
It is down -3.02% in the last 24 hours and up +12.91% over the past month.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
See More
Previous Close:
$142.53
Open:
$142.77
24h Volume:
661.18K
Relative Volume:
0.76
Market Cap:
$6.74B
Revenue:
-
Net Income/Loss:
$-192.89M
P/E Ratio:
-35.47
EPS:
-3.8976
Net Cash Flow:
$-172.97M
1W Performance:
+0.40%
1M Performance:
+12.91%
6M Performance:
+41.77%
1Y Performance:
+1,186%
1-Day Range:
$136.44
$142.81
1-Week Range:
$127.75
$142.81
52-Week Range:
$10.26
$151.02
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
138.23 | 6.95B | 0 | -192.89M | -172.97M | -3.8976 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Citizens | Mkt Outperform |
| Dec-12-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-22-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Why is Avoro Capital Advisors Making a Big Bet on Celcuity (CELC) - Kavout
Celcuity Inc. Advances SEC Compliance and Capital Markets Goals - Faegre Drinker Biddle & Reath LLP
Price-Driven Insight from (CELC) for Rule-Based Strategy - Stock Traders Daily
Celcuity Inc. Files Amendment No. 1 to Form 8-K/A with SEC for February 2026 Event - Minichart
Celcuity’s Gedatolisib Shines Amid Mounting Cash Burn - TipRanks
Celcuity Is Maintained at Buy by HC Wainwright & Co. - Moomoo
H.C. Wainwright Maintains Celcuity(CELC.US) With Buy Rating, Raises Target Price to $185 - Moomoo
Celcuity Shareholders Approve New 2026 Equity Incentive Plans - The Globe and Mail
Celcuity: Approaching An Inflection Point With Gedatolisib (NASDAQ:CELC) - Seeking Alpha
CELC Maintained by HC Wainwright & Co. -- Price Target Raised to $185 - GuruFocus
Citizens reiterates Celcuity stock rating ahead of July approval By Investing.com - Investing.com Australia
Celcuity (CELC) price target increased by 20.06% to 159.86 - MSN
Citizens reiterates Celcuity stock rating ahead of July approval - Investing.com UK
Celcuity stock price target raised to $185 by H.C. Wainwright - Investing.com UK
Celcuity stock price target raised to $185 by H.C. Wainwright By Investing.com - Investing.com Australia
UBS Group AG Reduces Stock Position in Celcuity, Inc. $CELC - MarketBeat
Celcuity Price Target Raised to $185.00/Share From $165.00 by HC Wainwright & Co. - Moomoo
Why Celcuity (CELC) Is Up 5.1% After VIKTORIA-1 Success And Pipeline ExpansionAnd What's Next - Sahm
Celcuity outlines VIKTORIA-2 expansion while targeting July 17 FDA decision for gedatolisib - MSN
LifeSci Capital Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $165 - Moomoo
Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst - Sahm
Celcuity (CELC) Gets a Buy from Stifel Nicolaus - The Globe and Mail
Celcuity Inc. (NASDAQ:CELC) Q1 2026 Earnings Call Transcript - Insider Monkey
Assessing Celcuity (CELC) Valuation After Positive VIKTORIA 1 Data And Upcoming FDA Decision - Yahoo Finance
Celcuity Q1 earnings call highlights - MSN
Celcuity’s Earnings Call: Strong Data, Rising Cash Burn - TipRanks
Celcuity (NASDAQ:CELC) Posts Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Stifel raises Celcuity stock price target on trial expansion potential - Investing.com UK
Celcuity's cancer drug expansion could ignite massive new market opportunity: Analyst - MSN
Analysts Are Bullish on Top Healthcare Stocks: Celcuity (CELC), Rubicon Organics (ROMJF) - The Globe and Mail
What's Going On With Celcuity Stock Friday?Celcuity (NASDAQ:CELC) - Benzinga
Stifel raises Celcuity stock price target on trial expansion potential By Investing.com - Investing.com Australia
Stifel Maintains Celcuity(CELC.US) With Buy Rating, Raises Target Price to $175 - Moomoo
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $157 to $183 - Moomoo
Celcuity Inc. Stock 12‑Month Price Target Raised to $167.18, Implies 24% Upside - TradingView
Celcuity Inc. Stock 12‑Month Price Target Raised to $164, Implies 22% Upside - TradingView
Celcuity Inc. Stock 12‑Month Price Target Raised to $159, Implies 18% Upside - TradingView
Celcuity Q1 2026 Earnings Call Transcript - MarketBeat
Celcuity Q1 Earnings Call Highlights - sharewise.com
CELC: Positive phase III data and commercial launch readiness mark a pivotal Q1 2026 - TradingView
Celcuity (CELC) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings call transcript: Celcuity’s Q1 2026 results beat expectations - Investing.com
Earnings call transcript: Celcuity’s Q1 2026 results beat expectations By Investing.com - Investing.com Canada
Transcript: Celcuity Q1 2026 Earnings Conference Call - Benzinga
Celcuity Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Celcuity Inc. (NASDAQ:CELC) Q1 Earnings Beat Forecasts, But Stock Drops on Phase 3 Data Focus - ChartMill
Celcuity posts narrower-than-feared Q1 loss By Investing.com - Investing.com South Africa
CELCUITY ($CELC) Releases Q1 2026 Earnings - Quiver Quantitative
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):